He is also convinced that the test could help improve the medical community's attitude toward panic disorder by giving it a biological basis.
"They think it's a character weakness," he said. "It's no different from obesity or diabetes. There are things you can do to decrease it, but if you're gonna get it, you're gonna get it. There's nothing you can do about it.
According to Philibert, 10 million people suffer from panic disorder. "It doesn't mean we're gonna vote you off the island," he said. "If it makes their day better, great. In the end, that's what it's about."
Dr. Beverly Yashar, assistant professor of human genetics at the University of Michigan, said that Philibert's test represents a recent shift in the medical community.
She noted that researchers are moving away from Mendelian genetics in which the belief is a change in one gene causes a disease, to genomic medicine in which changes in multiple genes are viewed as the cause of a disease. Multiple gene changes mean a higher susceptibility for developing a disease. It is also widely accepted that environment affects someone's susceptibility to a disease.
According to Yashar, the new trend in general diagnostics could lead to well-defined genetic signatures for everyone.
"Ultimately, this would be a way of developing a genomic signature, and it's that signature that becomes a potential diagnostic tool," she said.
However, Yashar is reluctant to refer to gene profiling tests as report cards.
"Report cards are a great idea," she said. "I wouldn't call it a report card because that's set in stone. I would rather call it a genetic signature."
The prospect of report cards or genetic signatures for everyone continues to raise troubling ethical questions and cause grave concern.
"There's a lot of concern in the genetic community," Yashar said. "Not everybody wants, nor is it appropriate to have that type of knowledge, because you might [get the disease] but not be sure."
She used the example of Huntington's disease to further illustrate her viewpoint. Though there exists a genetic test for the deadly condition, there is no cure.
"People with that family history don't get the test because there is nothing they can do about it," she said. "Many people choose not to have that info. Some people do, some don't. They may not want to know for a disease with no cure."
Glatt warned that another danger of report cards is overestimating the value of genetic test results.
"Genetic testing will have a limited predictive value, at least for behavioral disorders," he said. "The risk is [in attributing] a very powerful meaning to it, even for people who know the predictive power of genetic tests is very small."
But Glatt cautioned that overestimating the value of these tests could potentially lead to people being denied insurance or employment simply because they show a genetic risk for a disease.
According to company and industry estimates, molecular and genetic testing is a $2.2 billion industry.
"The clearest indication of the potential financial gain in this type of genetic testing is the increase in DTS -- direct to consumer genetic testing," Yashar said.
She remarked that private companies are now offering genetic tests to consumers without a physician even being involved. This trend benefits those who live in communities that are medically underserved.